Abstract | BACKGROUND: METHODS: Plasma VEGF, soluble (s) P-selectin and thrombin-anti- thrombin complex (TATc) were analyzed in 80 patients with therapeutically controlled essential hypertension and 40 age and sex-matched healthy normotensive controls. The effects of a 6-month treatment with aspirin 100 mg/day on VEGF levels of 20 hypertensive patients were also studied. RESULTS: Plasma VEGF (p<0.0001), sP- selectin (p=0.01) and TATc (p=0.02) levels were higher in hypertensives compared to controls. Multivariate analysis including age, sex, risk factors, cardiovascular disease, anti-hypertensive treatment, sP- selectin and TATc showed that only sP- selectin was an independent predictor of VEGF (beta=0.40, p<0.03). Aspirin treated hypertensives showed a significant reduction of sP- selectin (-26%, p<0.01) and VEGF (-33%, p<0.01) levels. Moreover, the reduction of plasma VEGF levels directly correlated with that of sP- selectin (Rho=0.46, p=0.04). CONCLUSIONS: In vivo activation of platelets in hypertensive patients is responsible for enhanced circulating VEGF levels, which are significantly lowered by aspirin treatment.
|
Authors | Patrizia Ferroni, Francesca Martini, Roberta D'Alessandro, Agesilao Magnapera, Valeria Raparelli, Antongiulio Scarno, Giovanni Davì, Stefania Basili, Fiorella Guadagni |
Journal | Clinica chimica acta; international journal of clinical chemistry
(Clin Chim Acta)
Vol. 388
Issue 1-2
Pg. 33-7
(Feb 2008)
ISSN: 0009-8981 [Print] Netherlands |
PMID | 18001701
(Publication Type: Journal Article)
|
Chemical References |
- P-Selectin
- Vascular Endothelial Growth Factor A
- Aspirin
|
Topics |
- Aged
- Aspirin
(pharmacology)
- Female
- Humans
- Hypertension
(blood)
- Male
- P-Selectin
(blood)
- Platelet Activation
(drug effects)
- Solubility
- Vascular Endothelial Growth Factor A
(blood)
|